Indian Pharma Sector: Why It's One of the Hottest Bets on Dalal Street Right Now
If you're tracking the Indian stock market in 2026, one sector that simply cannot be ignored is pharma. The Nifty Pharma Index, currently trading around ₹24,762, has been quietly building momentum while broader markets remain choppy. Here's everything you need to know about why pharma stocks in India deserve serious attention in your portfolio right now.
The Numbers Don't Lie: Six Months of Double-Digit Growth
India's pharmaceutical market recorded 12.1% year-on-year growth in May 2026, marking six consecutive months of double-digit expansion - the longest such sustained run in years. Nine out of ten major therapy categories posted double digit growth simultaneously. Analysts at Equirus called this growth "unusual," signaling a structural shift rather than a seasonal blip.
The Big Event: Biopharma SHAKTI - A ₹10,000 Crore Game Changer
The single biggest catalyst for the sector is the Union Budget 2026–27. The government launched the ₹10,000 crore Biopharma SHAKTI program to strengthen domestic manufacturing of biologics and biosimilars, positioning India as a global innovation and production hub.
The scheme will expand the National Institutes of Pharmaceutical Education and Research (NIPERs), create a large clinical trial network, and strengthen the Central Drugs Standard Control Organization (CDSCO). Additionally, Budget 2026–27 proposed a full exemption of basic customs duty on 17 cancer-related drugs, and separately, seven more rare diseases were added to the list eligible for import duty exemption on drugs and medicines imported for personal use.
This is a direct policy tailwind that long-term investors in healthcare stocks and biopharma stocks should not overlook.
Key Drivers Behind the Pharma Sector Rally
1. Domestic Market Boom Sales force expansion, improved productivity of medical representatives, deeper rural distribution, and new product launches are expected to support 8–10% revenue growth in the domestic market, driven by market share gains in chronic therapies and new product introductions.
2. Strong Export Engine Pharmaceutical exports exceeded $30.5 billion in FY25. India exports nearly 20% of the world's generic drugs, reinforcing its reputation as the "Pharmacy of the World."
3. PLI Scheme and API Self-Reliance The government is promoting indigenous manufacturing of high-value pharmaceutical products and critical Active Pharmaceutical Ingredients (APIs) through the Production-Linked Incentive (PLI) scheme, with three bulk drug parks sanctioned in Andhra Pradesh, Gujarat, and Himachal Pradesh.
4. Shift to High-Value Biologics India is moving from being a generics powerhouse to a biologics and biosimilars leader. The Biopharma SHAKTI initiative aims to capture 5% of the global biopharma market, responding to US tariff threats and supply chain vulnerabilities.
Risks to Watch
The US market outlook remains cautious, with growth expected to slow due to price erosion and regulatory scrutiny by the USFDA. The possibility of pharmaceutical tariffs by the US also remains a key monitorable.
Top Performing Pharma Stocks to Watch (Nifty Pharma Index)
Based on current market cap weightage in the Nifty Pharma Index:
On the fundamentals side, Dr. Reddy's stands out with five-year PAT growth of 82%, ROE of 20%, and ROCE of 25%. Divi's Laboratories, a key API manufacturer, remains one of the most financially disciplined companies in the sector - posting a 13% year-on-year rise in PAT to ₹751 crore in Q4 FY26, with an EBITDA margin of ~33% for the quarter, and carrying virtually zero debt on its balance sheet.
The Jarvis Invest View
At Jarvis Invest, our AI-driven equity advisory engine continuously tracks sectoral momentum, macroeconomic signals, and stock-level fundamentals in real time - and the Indian pharma sector is firmly on our radar. With six consecutive months of double-digit industry growth, strong policy tailwinds from the Biopharma SHAKTI program, & top Nifty Pharma constituents delivering consistent financial performance, our AI has identified this as a high-conviction sector for 2026. If you haven't yet reviewed your equity exposure to pharma, now is the time.
